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The effects of atropine on respiratory sinus arrhythmia 
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P. M. LEHRER, S. M. HOCHRON, L. RAUSCH AND R. CARR 
UMDNJ- Robert Wood Johnson Medical School, Piscataway, NJ, U.S.A. 
Heart rate is rhythmically related to respiratory rate, in a phenomenon known as respiratory sinus 
arrhythmia (RSA). Amplitude of RSA has been found to be an accurate noninvasive measure of vagal tone 
in the normal population. The purpose of this study was to examine the relationship between RSA and 
cardiac vagal tone among asthmatics, a group which has been described as having elevated RSA. This was 
accomplished by examining the effects of atropine on RSA in asthmatics, and comparing the results to 
those obtained elsewhere among normal subjects. Atropine at a dose of 1 mg/75 kg body weight was 
administered to 18 asthmatics, and produced decreases in RSA, equivalent to those previously found 
among normal subjects. The results suggest that the relationship between cardiac vagal tone and RSA is 
unaffected by the presence of asthma. 
Introduction 
Heart rate fluctuates cyclically with respiratory 
rate in a phenomenon known as respiratory sinus 
arrhythmia (RSA). Amplitude of RSA has been 
found to be an accurate and noninvasive measure of 
cardiac vagal tone in the normal population (l-3). 
Changes in vagus nerve activity induced by pharma- 
cological agents, electrical stimulation, surgery, and 
various disease processes are all sensitively reflected 
by RSA (l-3). 
However, it is not known whether RSA is a valid 
measure of cardiac vagal tone among asthmatics, 
because of the complexity of the interrelationship 
between breathing and cardiac rhythm. The presence 
of asthma has been linked to RSA elevations (4), but 
this does not definitively prove that vagal tone is 
elevated in asthma, because it remains possible that 
the respiratory abnormalities accompanying asthma 
may obscure the relationship between RSA and vagal 
tone. This study was therefore designed to test the 
effects of parenteral atropine on RSA amplitude in 
asthma, and to compare atropine-produced RSA 
changes among asthmatics with those produced by 
equivalent doses of atropine given to normal subjects 
in a previous study (5). 
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Methodology 
SUBJECTS 
Eighteen asthmatic adults between the ages of 18 
and 40, ten female and eight male, were studied. The 
experiment required two sessions, for which subjects 
were paid a total of $125. Subjects came to the 
screening session by word of mouth, by advertise- 
ment, through private physician referrals, and from 
the pool of persons who had previously participated 
in asthma research protocols. The diagnosis of 
asthma was confirmed by a board certified pulmo- 
nary physician (S.H.), after spirometric studies, 
histories and physical examinations. 
The following criteria were all required for par- 
ticipation in the study, unless asthma had previ- 
ously been confirmed by a methacholine challenge 
test. A history of recurrent asthma (wheeze which 
responded to beta-2 aerosol therapy) within the 
prior 12 months, a prior clinical diagnosis of 
asthma, and abnormal spirometry (FEV, < SO%, 
FEF,,<GO%) with no evidence of restrictive lung 
disease. Ten subjects had previously, within a year 
of testing, completed methacholine challenge tests 
with abnormal results. Two of these subjects were 
included in the present study despite normal 
spirometry findings on the day of testing, because 
the methacholine challenge test is considered to be 
definitive for detecting asthma (6). Pulmonary func- 
tion test and methacholine challenge test data are 
presented in Table 1. 
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Table I Subject characteristics and individual pulmonary data 
Subject 
no. Order* 
FEV, FEF,, 
Placebo Atropine Atropine Placebo 
MCT Data 
Pre Post Pre Post Pre Post Pre Post (PD 20) 
420 PIa 13 14 55 26 98 II 23 6 
435 alp 34 38 41 45 9 11 14 23 2 
436 PIa 51 53 55 43 14 23 17 14 
450 alp 82 82 80 83 64 67 63 63 4 
461 a/P 93 69 59 70 86 45 35 54 2 
479 a/P 52 65 69 71 17 31 35 38 
482 PIa 102 99 98 99 71 62 58 63 5 
486 a/P 32 31 28 21 11 10 9 9 3 
496 PIa 78 81 84 83 41 50 53 50 4 
497 a/P 93 102 100 93 55 82 70 65 4 
498 PIa 81 86 81 86 43 108 38 42 2 
501 alp 42 46 48 48 11 16 10 11 
503 PIa 46 68 63 66 17 30 30 31 
504 PIa 97 102 98 98 80 126 98 95 5 
505 PIa 91 81 79 78 71 56 59 53 5 
506 PIa 43 56 44 45 14 26 17 19 
508 PIa 40 53 51 59 15 24 27 21 
525 PIa 20 22 16 17 24 29 12 16 
*The order ‘pla’ represents placebo given in the first testing session, and atropine in the second. The order ‘a/p’ represents 
the opposite order 
Subjects were excluded for any of the following 
reasons: a history of chronic bronchitis or sinusitis, 
history or physical findings consistent with emphy- 
sema or non-asthma respiratory disease, a history of 
smoking cigarettes within the past 2 years, presence 
of cardiovascular or neurological disease, or psychi- 
atric disorders requiring the administration of psy- 
choactive medication. 
Subjects refrained from using bronchodilator 
medication for 12 h before screening spirometry, and 
avoided caffeine on the day of testing. Informed 
consent was obtained at the beginning of the first 
session, after each subject was provided with written 
and verbal descriptions of all procedures and all 
anticipated drug effects. The procedures were 
approved by the committee for protection of human 
subjects of Robert Wood Johnson Medical School. 
For subjects who had received it, the methacholine 
challenge test used the five-breath method, following 
the standard procedures described by Chai, et al. (6) 
Accordingly, subjects were administered increasing 
doses of methacholine until a 20% decrease in FEV, 
was achieved, to a maximum of nine doses. Subjects 
who tolerated nine doses of methacholine without a 
20% decrement in FEV, were excluded from the 
study, regardless of spirometry results, asthma his- 
tory, or other findings. 
EQUIPMENT 
Spirometry was recorded on a water seal spi- 
rometer (Collins Pulmonary Testing System DS2). 
For assessing cardiac vagal tone, electrocardiogram 
signal (EKG) was amplified on a customized AC 
amplifier and recorded on a Series 700 Vetter Model 
A tape recorder. At a later time it was played back 
through a Delta-Biometrics Vagal Tone Monitor. 
(This instrument analyses average peak-to-trough 
amplitude of heart period variability at respiratory 
frequencies (7). In this study, a frequency range of 
0.12-0.40 Hz was used, which corresponds to adult 
respiratory rhythm. The digital filter was calculated 
as described by Bohrer and Porges (8). The vagal 
tone monitor produced the k statistic, a measure of 
RSA amplitude (the log, of the average peak-to- 
trough amplitude in heart period, in ms, for fluctua- 
tions occurring in the prescribed frequency band). 
This statistic was originally described in the patent 
for the device (9) and has subsequently been 
described by others in the journal literature (10). The 
formula and equipment for assessing and computing 
k was derived from studies using cross-spectral 
analysis to determine the proportion of the periodic 
fluctuations in heart period that occur within the 
expected respiratory frequencies for an adult human 
population. 
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SETTING AND EXPERIMENTERS 
Spirometry testing and the administration of 
medication were performed by a board certified 
pulmonary physician. Double-blind procedures were 
used, such that neither the physician nor the patient 
was told whether active drug or placebo was being 
administered in any given session. 
GENERAL PROCEDURE FOR THE STUDY 
Subjects were seen on two separate occasions, 
separated by between 2 days and 1 month. The 
order of placebo/active drug was randomized, using 
a table of random numbers. Half the subjects were 
tested with the drug in the first session and half 
with the placebo. Subjects received the other condi- 
tion (drug or placebo) in the second session. For 
each subject, both sessions were held during an 
afternoon visit at approximately the same time of 
day, in order to minimize the effects of diurnal 
variation in asthma. 
Upon subjects’ arrival, resting EKG was recorded 
for 5 min. During this procedure, subjects were 
instructed to sit comfortably in a straight back 
chair, with eyes closed, and to remain still. Follow- 
ing EKG recording, flow volume loops were 
obtained using standard technique. Three forced 
expiratory manoeuvres were performed using maxi- 
mal effort. If equivalent flow volume curves were 
achieved (i.e., FEV,+FVC within 5%) the curve 
with the highest FEV,+FVC was chosen for analy- 
sis. Subjects were then injected with atropine or 
placebo, as described below. If equivalent curves 
were not obtained, additional manoeuvres were 
done until three equivalent curves were obtained. If 
equivalent curves could not be obtained, the curve 
with the highest value of FEV,+FVC was scored 
(11). 
After the injection, subjects were asked to remain 
in the waiting room for 30 min. Thereafter, EKG and 
spirometry tests were administered exactly as 
described above. 
PROCEDURE FOR ADMINISTERING MEDICATION 
In each session, subjects received an injection in the 
deltoid muscle of either atropine sulphate (1 mg/ 
75 kg body weight) or placebo (normal saline). This 
dose of atropine sulphate has previously been found 
to produce significant decreases in cardiac vagal tone 
in a normal population (5). For the placebo con- 
dition, the same quantity of normal saline was 
injected. To preserve double blind conditions, the 
syringes were filled from identically-appearing vials 
of atropine sulphate and placebo. 
STATISTICAL ANALYSIS 
Statistical analysis was performed on a PC-AT 
computer, utilizing the SAS Version 6.03 software 
package (12). 
Results 
Table 1 defines the study group’s distribution of 
asthma severity for each day of testing. On each 
day, in approximately half the subjects, asthma was 
moderate (FEV,=40-60%) or severe (FEV,<40%). 
As can be seen in Table 1, some subjects had normal 
pulmonary function on the day of testing, despite a 
history of asthma, as defined above. 
To determine whether the dose of atropine was 
sufficient to produce measurable bronchodilation, 
spirometry data (FEV,, FEF,,, FVC) were submitted 
to a repeated measures multivariate analysis of vari- 
ance (MANOVA). The statistical model included one 
between-groups factor, ORDER of drug administra- 
tion (atropine in the first session and placebo in the 
second, versus the opposite order), and two repeated 
measures, DRUG (vs. placebo) and PRE/POST (i.e. 
before drug administration vs. afterward). A signifi- 
cant (P<O.O4) interaction between DRUG and PRE/ 
POST was found using Wilks’ Lambda statistic. The 
MANOVA was followed by separate univariate 
analyses for each spirometry variable. As demon- 
strated in Table 2, atropine, on the average, produced 
bronchodilation. However, as demonstrated in Table 
1, this did not occur to a clinically significant extent 
in many subjects, primarily because of near-normal 
pretest spirometry values in those subjects on the day 
of testing. 
Also, as shown in Table 3, relative to placebo, 
atropine significantly decreased both RSA and car- 
diac interbeat interval (defined as time, in ms, 
between EKG r spikes). The size in decrement of 
RSA is almost precisely the same as found among 
normal subjects in a study by Dellinger et aZ., using 
the same dose of atropine, at the same period of time 
after drug-administration (5). The mean decrease in 
p from the former study was 1.8, while in the current 
study it was 1.5, a nonsignificant and inconsequential 
difference. Baseline vagal tone was higher in the 
previous study, however (7.4, vs. 6.0 in the present 
study), presumably because of a somewhat younger 
age range (19-30). 
Discussion 
As reflected in the response to parenteral atropine, 
the relationship between RSA and cardiac vagal tone 
among asthmatics is similar to that observed among 
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Table 2 Effects of atropine on spirometric measures 
Atropine Placebo 
Pre Post Pre Post 
Spirometry 
variable M M SD M SD M SD M SD F (d.f.)* PC 
FEV, 18 2.28 0.84 249 0.79 2.32 0.71 2.29 0.79 8.57 (1,17) 0.01 
FEV,/FVC 17 625 13.9 70.4 15.2 65.4 11-7 67.1 116 6.20 (1,16) 0.03 
FEF,,% 18 2.17 1.61 2.70 1.74 1.92 1.08 2.00 1.06 3.82 (1,17) 0.07 
*The F ratios are for the Drug by PrelPost interaction. 
Table 3 Effects of atropine on cardiac vagal tone and cardiac interbeat interval 
Measure n 
Atropine Placebo 
Pre Post Pre Post 
M SD M SD M SD M SD F (d.f.)* P< 
tit 12 6.16 1.39 4.59 2.07 5.56 1.29 6.00 1.41 8.21 (122) 0.01 
IBI$ 12 806 129 725 126 756 80 791 90 13.05 (124 0.002 
*F ratios are for the Drug x Pre/Post interaction. 
tPorges’ prepresents the amplitude of respiratory sinus arrhythmia, a measure of vagal tone. It is expressed as log, ms (2). 
$Cardiac interbeat intervals are expressed in ms. 
normal subjects. While baseline RSA was lower in 
the present study, the decrease in RSA following 
atropine was almost precisely the same as that 
observed by Dellinger et al. (5) among a group of 
normal subjects, at the same dosage. In both studies, 
subjects were tested at the same interval after admin- 
istration of the drug. In this study, as in the study by 
Dellinger et al., only partial vagal blockade was 
obtained at this dose. It would be expected that a 
higher dose would produce complete blockade, as has 
been shown in the previously published literature. 
(Because of the discomfort and risks involved in 
complete vagal blockade, we decided not to use a 
higher dose in the current study.) The pattern of 
correlations between expiratory flow rates and RSA 
demonstrate that changes in flow rates produced by 
atropine were related to changes in vagal tone, as 
reflected in RSA. The data also show that initial 
degree of airway obstruction did not affect this 
relationship. 
The results of this study therefore indicate that the 
relationship between vagal tone and RSA is not 
affected by the presence of asthma. This supports the 
validity of RSA as an index of vagal tone in the 
asthmatic population. Further examination of dose- 
dependent changes would be needed to determine 
whether, as in normal subjects, RSA can precisely 
predict variations in vagal tone among asthmatics. 
Because of the noninvasiveness of RSA and its ease 
of measurement, such work is warranted. 
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